MARKET

LTRN

LTRN

Lantern Pharma Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.80
-0.22
-1.37%
Opening 10:51 04/23 EDT
OPEN
16.21
PREV CLOSE
16.02
HIGH
16.21
LOW
15.80
VOLUME
9.50K
TURNOVER
--
52 WEEK HIGH
24.84
52 WEEK LOW
10.40
MARKET CAP
176.67M
P/E (TTM)
-16.6036
1D
5D
1M
3M
1Y
5Y
Lantern Pharma to Participate in the Virtual 20th Annual Needham Healthcare Conference
PR Newswire - PRF · 04/06 11:45
Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins
PR Newswire · 04/01 12:59
Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference
Exciting and insightful biotech news was front and center at the Benzinga Biotech Small Cap Conference, a two-day event that kicked off virtually Wednesday.
Benzinga · 03/25 18:45
Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021
9:25 a.m. EDT - Lantern Pharma (LTRN) CEO, Panna Sharma 9:25 a.m. - AcelRx Pharma (ACRX) CEO, Vincent Angotti 9:45 a.m. - Kintara Therapeutics (KTRA) CEO, Saiid Zarrabian 9:45 a.m. - Lexaria Bioscience (LEXX) Chair,
Benzinga · 03/23 23:12
BRIEF-Lantern Pharma To Present New Data Supporting The Advancement Of LP-184
reuters.com · 03/23 11:50
Lantern Pharma To Present Data Supporting Advancement Of LP-184 At AACR Virtual Annual Meeting 2021 Apr. 20-15
Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, will
Benzinga · 03/23 11:50
Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021
, March 23, 2021 /PRNewswire/ -- (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, will present new data on LP-184, a next-...
PR Newswire - PRF · 03/23 11:48
LTRN: New Programs, Pipeline Progress, Raise, and RADR
By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Fourth Quarter and Full Year 2020 Financial and Operational Results On March 10, 2021, Lantern Pharma, Inc. (NASDAQ:LTRN) announced fourth quarter and full year 2020 financial and ope...
Zacks Small Cap Research · 03/22 14:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LTRN. Analyze the recent business situations of Lantern Pharma Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LTRN stock price target is 28.00 with a high estimate of 30.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 11
Institutional Holdings: 83.00K
% Owned: 0.74%
Shares Outstanding: 11.18M
TypeInstitutionsShares
Increased
3
6.82K
New
3
11.37K
Decreased
3
9.68K
Sold Out
5
85.65K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.08%
Pharmaceuticals & Medical Research
+0.46%
Key Executives
Chairman/Independent Director
Donald Keyser
Chief Financial Officer/Primary Contact
Jeff Thomas
President/Chief Executive Officer/Director
Panna Sharma
Chief Financial Officer/Secretary
David Margrave
Chief Scientific Officer
Kishor Bhatia
Director
David Silberstein
Independent Director
Vijay Chandru
Independent Director
Leslie Kreis
Independent Director
Franklyn Prendergast
No Data
  • All
  • Financials
  • Insiders
More
About LTRN
Lantern Pharma Inc. is a clinical stage biotechnology company. The Company is focused on developing oncology therapies. It uses its artificial intelligence (AI) platform, RADR, which includes data points, and uses big data analytics to uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that benefits from its compounds. Its portfolio consists of three compounds: LP-100, LP-300 and LP-184. The Company is developing LP-100 for metastatic, castration-resistant, prostate cancer (mCRPC). LP-300 is a small molecule with cysteine modifying activity on select protein. LP-184, is in a preclinical translational ex vivo study using fresh human biopsies. LP-184 is an alkylating agent with nanomolar potency that preferentially damages deoxyribonucleic acid (DNA) in cancer cells that overexpress certain biomarkers.

Webull offers kinds of Lantern Pharma Inc. stock information, including NASDAQ:LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.